Dabigatran Compared With Warfarin for Stroke Prevention With Atrial Fibrillation: Experience in Hong Kong
Article first published online: 25 OCT 2012
© 2012 Wiley Periodicals, Inc.
Volume 35, Issue 12, pages E40–E45, December 2012
How to Cite
Ho, J. C. S., Chang, A. M., Yan, B. P., Yu, C. M., Lam, Y. Y. and Lee, V. W. Y. (2012), Dabigatran Compared With Warfarin for Stroke Prevention With Atrial Fibrillation: Experience in Hong Kong. Clin Cardiol, 35: E40–E45. doi: 10.1002/clc.22069
- Issue published online: 7 DEC 2012
- Article first published online: 25 OCT 2012
- Manuscript Accepted: 23 SEP 2012
- Manuscript Received: 15 AUG 2012
- 10Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151., , , et al.
- 11Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thrombost Haemost. 2005;3:692–694., ;
- 122011. http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/UserGuide_EQ-5D-5L.pdf. Accessed August 5, 2012., , , et al. EQ−5D−5L User Guide Version 1.0. EuroQol Group Executive Office;
- 13EuroQol Group, 2012. EQ-5D-5L crosswalk value sets. http://www.euroqol.org/fileadmin/user_upload/Documenten/Excel/Crosswalk_5L/EQ-5D-5L_Crosswalk_Value_Sets.xls. Accessed August 1, 2012
- 14Dabigatran use in the real world: preliminary results of a prospective trial comparing outcomes with dabigatran and warfarin therapy. Proceedings of the Thrombosis and Hemostasis Summit of North America: research abstracts. Am J Hematol. 2012;87: S146–S200., , , et al.
- 152012. http://www.theheart.org/article/1380849.do. Accessed August 5, 2012.Oral anticoagulants in the real world: bleeding rates and medical costs compared. The Heart.org. April 2,
- 19Pradaxa (dabigatran etexilate) [package insert]. Hong Kong: Boehringer Ingelheim Ltd.; 2011.
- 202012. http://www.clinicaltrials.gov/ct2/show/NCT00808067. Accessed August 5, 2012.of Health. RELY-ABLE Long-Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial.